Home » Topics » Regulatory » EMA

EMA
RSS

European Commission approves Ledaga for mycosis fungoides-type CTCL

March 7, 2017

EMA grants orphan drug designation to Resolaris for limb girdle muscular dystrophy

March 6, 2017

EMA grants SPK-9001 access to PRIME program for hemophilia B

March 6, 2017

EMA grants PRIME access to givosiran for acute hepatic porphyrias

March 2, 2017

EMA committee hands down positive opinion for 8-week regimen of Viekirax + Exviera

March 1, 2017

EMA committee hands down positive opinion for Varuby

Feb. 27, 2017

EMA committee recommends broadening approval of Darzalex

Feb. 27, 2017

Tafinlar plus Mekinist granted positive opinion in E.U. for BRAF-positive NSCLC

Feb. 27, 2017

EMA CHMP gives positive opinion on ZS-9 for hyperkalemia

Feb. 27, 2017

EMA committee supports conditional marketing approval for Shire's Natpar

Feb. 27, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...